Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
British Journal of Cancer,

Feun LG et al. – Arginine–depleting therapy with pegylated arginine deiminase (ADI–PEG20) is safe and the drug is only efficacious in melanoma patients whose tumour has negative argininosuccinate synthetase (ASS) expression. Argininosuccinate synthetase tumour positivity is associated with drug resistance and tumour progression.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore